Skip to main content

Table 4 Baseline data on the patients, continuous variables

From: RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale

  Double dose of statin Statin + ezetimibe p value
  mean ± sd n mean ± sd n
age 62.6 ± 9.5 56 61.7 ± 11.1 53 0.4949
TC 218.2 ± 27.2 56 212.5 ± 30.1 53 0.3567
TG 161.9 ± 88.3 56 146.7 ± 95.2 53 0.1803
HDL-C 54.7 ± 9.6 56 56.7 ± 15.2 53 0.9734
LDL-C 135.2 ± 22.6 56 130.6 ± 19.2 53 0.5463
non HDL-C 163.6 ± 25.7 56 155.9 ± 26.9 52 0.1133
RLP-C 6.3 ± 3.9 56 6.1 ± 4.8 52 0.4756
apo A1 146.6 ± 16.6 44 144.2 ± 19.2 40 0.3288
apo B 111.4 ± 18.2 44 101.8 ± 16.5 40 0.0152
apo E 4.1 ± 0.9 44 3.8 ± 1.0 40 0.1604
MDA-LDL 157.0 ± 62.0 12 112.6 ± 27.7 9 0.0549
sd-LDL 52.2 ± 17.9 56 46.2 ± 16.0 52 0.0484
Fasting glucose 132.7 ± 32.5 56 141.5 ± 33.1 53 0.1108
Fasting insulin 10.9 ± 7.0 35 13.8 ± 12.5 28 0.5381
ALT 23.6 ± 10.9 56 24.7 ± 12.5 53 0.8318
AST 23.1 ± 12.1 52 23.7 ± 12.2 49 0.8541
γ-GTP 30.2 ± 21.7 53 28.6 ± 26.6 47 0.3248
CK 116.7 ± 58.2 54 122.5 ± 88.3 51 0.9642
Creatinine 0.81 ± 0.28 56 0.79 ± 0.24 51 0.9627
HbA1C 7.15 ± 1.32 56 7.25 ± 0.64 53 0.6294
hs-CRP 1114 ± 1493 56 922 ± 1119 51 0.6025
  1. The data were evaluated using the Wilcoxon test.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X